The Association of the British Pharmaceutical Industry
Medicines are transforming our lives like never before.
We want the UK to be the best place in the world to research, develop and use the medicines and vaccines of the future.
- VALUING AND ACCESSING MEDICINES
- RESEARCH, DEVELOPMENT AND MANUFACTURING
- WORKING IN PARTNERSHIP
- INDUSTRY REPUTATION
- INTERNATIONAL, TRADE AND IP
- HEALTH DATA
VALUING AND ACCESSING MEDICINES
Value and Access
Medicines bring huge value to NHS patients. The development of new medicines is uncertain, costly, and involves significant rates of failure. The pharmaceutical industry spends $160 billion per year on research and development.The private sector produces nearly all the medicines and vaccines available to us. Companies need to make a profit – and a return – on global investment in order to maintain investment in the next generation of medicines.
RESEARCH, DEVELOPMENT AND MANUFACTURING
R & D Manufacturing
We're helping to build a thriving environment for medicine discovery so the UK can be the best place in the world to research and develop new medicines and vaccines.
WORKING IN PARTNERSHIP
Partnerships
We have a long-standing positive relationship with the NHS, and a record of facilitate the same across various parties across the Life Sciences sector. We believe in focusing collaboration on where it can add the most value in making innovation as widely available to patients as possible.
INDUSTRY REPUTATION
Reputation
Everywhere, every day someone relies on the results of our work to ensure their health and wellbeing. We are proud of this and are committed to working with a wide range of people - patients, doctors, nurses, regulators and governments - in order to deliver medicines in an ethically responsible way. Patients are at the heart of everything that we do.
INTERNATIONAL, TRADE AND IP
International, trade and IP
The ABPI is working to ensure that the UK has the best relationship with our international partners for patients, public health and the life sciences sector.
HEALTH DATA
Health data
We aim to harness the UK’s health data to support the efficient design, feasibility, recruitment and conduct of the full range of clinical trials. We are helping the UK make the most of health-related data for future research and development into new medicines.
MMIP: Fulfilling the potential identified in the Government’s Life Sciences Vision
Read the latest report from the Medicines Manufacturing Industry Partnership (MMIP) on how we need to boost medicines manufacturing in the UK.
Read the reportLatest news
Pinder Sahota to step down as APBI President
Pinder Sahota has made the decision to resign as President of the ABPI.
Pharma industry urges halt to further rises in record revenue clawbacks
The pharmaceutical industry is calling on the government to scrap plans to raise the statutory revenue clawback rate from 24.5% to a record 27.5%. Doing so is a fundamental first step to reassuring investors about the UK’s ambition to halt the contraction of UK life sciences, and to secure a positive outcome to critical upcoming negotiations with the industry.
ABPI response to new MHRA fees announced for 1 April 2023
The MHRA have published their response to the consultation on proposals for changes to their statutory fees, which will come into effect on 1 April 2023.
ABPI response to MHRA European Commission Decision Reliance Procedure (ECDRP) announcement
Decision on The European Commission Decision Reliance Procedure (ECDRP) in GB.
Latest blogs and events
PMCPA | launch of social media guidance
PLEASE NOTE THIS WEBINAR IS NOW FULL.
The Prescription Medicines Code of Practice Authority (PMCPA) has published new social media guidance to help pharmaceutical companies apply the high standards demanded by the industry’s Code of Practice to all their online communications channels.
Inspiring the next generation of STEM workers
Blog by Andrew Croydon, ABPI Director of Skills & Education Policy and Examinations
By coming together, we can overcome antimicrobial resistance
Reflections on World Antimicrobial Awareness Week 2022 from Dr Amit Aggarwal, ABPI Executive Director, Medical Affairs.
Reflections from NICON22
Commentary on this year's Northern Ireland Annual Conference and Exhibition 2022.
Key content hubs
We stand in solidarity with the people of Ukraine and condemn the invasion of their country. As an industry dedicated to saving lives, we stand for peace.
As a critical part of the health care community in the UK, the pharmaceutical industry wants to play the biggest possible role in the response to COVID-19.
The ABPI Code of Practice sets out the requirements the industry must comply with and supports companies’ commitment to self-regulation and to operate in a professional, ethical and transparent manner.
The ABPI is committed to providing clear and accurate information for patients and the public.
— ABPI (@ABPI_UK) February 3, 2023
We have been recognised as a trusted health care information creator by the @PiFonline for online health and care resources.
Read more here: https://t.co/MIv0apBViL #PIFtick
This demonstrates the amazing progress which can happen when industry-driven innovation in medicines is partnered with fantastic NHS care and delivery.
— ABPI (@ABPI_UK) February 2, 2023
In countries where #HPV uptake is strong, there are fewer precancerous and abnormal cells recorded. Vaccines are safe and effective. Get vaccinated, make vaccines work #WeWontRest #WorldCancerDay #UnitedInProtection pic.twitter.com/F4ZGV3OCVN
— VaccinesEurope (@VaccinesEurope) February 2, 2023
To ensure we are prepared for future pandemics, it is crucial to:
— IFPMA (@IFPMA) February 1, 2023
✅Accelerate R&D toward innovative vaccines & therapeutics
✅Integrate🌍surveillance efforts
✅Harmonize regulatory processes
More in the #100DaysMission Implementation Report ➡️https://t.co/5wso9gnisR pic.twitter.com/KLH6yifQJ1
The Pharmaceutical Industry in the UK
![R and D Investment [3]](/media/ouqnhlry/figures-r-d-investment-5-0bn.jpg)
Publications
- ABPI Statutory Scheme consultation response executive summary - 31 January 2023
- Fulfilling the potential identified in the Government’s Life Sciences Vision
- Transforming lives, improving health outcomes: tackling the true cost of variation in uptake of innovative medicines
Members
Online members portal (ABPI Meetings via Adam.ai)
ABPI members can log in for bespoke content and services.